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Glycated human serum albuminA simple, sensitive, fast, and economical HPLC method was developed and validated for simultaneous
estimation of two fixed dose combinations frequently prescribed in diabetes (Metformin plus
Glibenclamide) and hypertension with dyslipidemia (Amlodipine plus Atorvastatin) in Human plasma
for the first time. The validated HPLC method was used to quantify the concentration of selected actives
in ultrafiltrate. Optimum separation conditions were obtained with Water’s Novapack Phenyl
(150 mm  4.6 mm, i.d., 5.0 lm) column with mobile phase consisting of 0.1% Phosphoric acid (pH
3.0) and acetonitrile (ACN) in gradient mode with column oven temperature maintained at 30 C and elu-
tion monitored by a UV detector at 227 nm. Protein precipitation was employed to extract the selected
analyte form human plasma. The recoveries were more than 90% for all analytes in cold aqueous 10% tri-
chloroacetic acid (TCA) and acetonitrile. The optimized HPLC-UV was validated in the calibration range of
10–10,000 ng mL1 for Metformin, 25–5000 ng mL1 for amlodipine, 50–10,000 ng mL1 for gliben-
clamide and 10–5000 ng mL1 for atorvastatin. The mean relative error was least when weighing of
1/2 was applied for calibration curve. The accuracy of samples for six replicate measurements at
LLOQ level was within limit. The precision and accuracy of samples for six replicate measurements at
LLOQ level was within limit. The validated method was applied for quantitation of selected analytes in
ultrafiltrate from protein binding experiments. A four to five fold increase in unbound fraction was
observed when spiked to human serum albumin. Further the unbound fraction of highly albumin bound
drugs was increased nearly to double when incubated with Gly-HSA as compare to HSA.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Type 2 diabetes (T2DM) involves alterations in a number of
metabolic pathways. In addition to alteration in glucose metabo-
lism, patients with T2DM are more likely to have concomitant/sec-
ondary complications such as adverse cardiac events [1],
hypertension [2] and dyslipidemia [3] that may lead to microvas-
cular and macrovascular complications.
Patients with T2DM have a two to four time higher death toll
due to cardiovascular diseases than people without the diabetes[4]. Precise pharmacotherapies for hypertension and dyslipidemia
to modify multiple microvascular and macrovascular events
reduce the risk of such events [5] and mortality [6] in patients with
T2DM. Rigid control over blood pressure and setting goals, below
those for the non-diabetic subject, have been shown to be effective
in lowering cardiovascular events and mortality in the diabetic
patient [7]. To achieve these goals in most cases, three to six
actives from different pharmacotherapies need to be prescribed
[8–11]. The primary therapy for suppression of the renin–an-
giotensin system (RAS) should be angiotensin 2 receptor blockers
and/or angiotensin-converting enzyme inhibitors/calcium channel
blocker with a renin inhibitor [12].
The primary oral antidiabetic (OAD) pharmacotherapies for
T2DM are metformin alone or in combination with the second gen-
eration sulfonylureas viz. gliclazide, glimperide, glipizide andformin,
(2016),
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gliclazide or glibenclamide are available commercially as single
tablets. Recently, several fixed dose combinations of Metformin
with sulfonylurea has been banned by Indian government [14]
except for Metformin with glyburide (glibenclamide) [15]. Never-
theless Metformin and Glimepiride combination provides greater
reductions in HbA1C and fasting plasma glucose compared with
metformin plus glibenclamide in T2DM15 but glibenclamide pro-
vides effective, convenient and better tolerance as compare to
other sulfonylureas when combined with Metformin [16]. Various
analytical procedures have been reported for simultaneous estima-
tion of Metformin and Glibenclamide viz. HPTLC, and liquid chro-
matographic methods coupled with UV-Spectroscopy [17], mass
spectrometry [18] and tandem mass spectrometry [19].
Many patients with diabetes and cardiovascular disease require
treatment for several different pharmacotherapies, the concept of
combining agents and/or fixed dose combinations with distinctly
different indications has become a veracity of treatment [20]. A
fixed-dose combination of atorvastatin and amlodipine is com-
monly prescribed as first line concomitant treatment to diabetic
hypertensive subjects [21]. Single pill therapy or fixed dose combi-
nation of Amlodipine and atorvastatin creates positive effect on
fibrinolytic balance and better BP control in hypertensive patients
with T2DM [22].
Though Metformin does not bound to serum albumin (albumin
binding <5%) but it induce conformational change in serum albu-
min structure [23]. Metformin inhibits the production of glycated
albumin in a concentration dependent fashion [24] and reduce pro-
duction of toxic dicarbonyls and Advanced Glycation End products
(AGEs) [25]. Sulfonylurea drugs are extensively bounded to serum
albumin and displacement of sulfonylurea drugs from their respec-
tive binding sites, predominantly by non-ionic actives may create
short term to severe hypoglycemic state in diabetic patients [26].
Clarithromycin have been reported to displace Glipizide and
Glibenclamide from their protein binding sites, thereby increasing
the unbound or free fraction of the drug [27].
An elevated level of glycated albumin has been observed in the
diabetic patients [28]. About 30% of serum albumin has been
reported to be glycated via non-enzymatic addition of reducing sug-
ars or their reactive degradation products to primary or secondary
amine groups on albumin [29,30]. The glycosylation of serum albu-
min is time dependent non-enzymatic process [24] and it impairs
the binding capacity of high protein bound drugs [31].
Given this background, the present study was envisaged to
evaluate the effect of amlodipine and atorvastatin combination
on serum albumin and glycated albumin binding capacity of met-
formin and Glibenclamide vice versa. The selected actives were
quantified in filtrate of ultrafiltration protein binding experiments
using validated liquid chromatographic method coupled to UV
detection. The HPLC-UV method was validated as per USFDA
guideline on bioanalytical method validation [32].
2. Experimental
2.1. Chemical and reagents
Qualified standards of Amlodipine besylate, Glibenclamide,
Atorvastatin calcium, Ranitidine Hydrochloride and Rosiglitazone
were a gift from Torrent Research Centre (Ahmadabad, India).
The qualified standards of Metformin Hydrochloride, recombinant
Human Serum Albumin (rHSA) and glycated Human Serum Albu-
min (Gly-HSA) were purchased from Sigma Aldrich (Bangalore,
India). Analytical/HPLC grade chemicals and solvents were
obtained from Ranbaxy Fine Chemicals Limited (Delhi, India).
Amicon Ultra centrifugal filtration devices (MWCO: 10 kDa) were
purchased from Millipore (Bangalore, India).Please cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
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A high-performance liquid chromatographic system (JASCO,
Kyoto, Japan) composed of a PU-2089 plus Quaternary pump sol-
vent delivery module, a manual rheodyne injector with a 20 lL
fixed loop and a UV-2075 intelligent UV–Visible detector. For sta-
tistical calculations in bioanalytical method validation Graphpad
PRISM version 5.1 for Windows, (Graphpad software Inc., Califor-
nia, USA) software was used.
AMLO, GLBN and ATOR were less soluble in water and freely
soluble in selected organic solvents like methanol (MeOH), ace-
tonitrile (ACN), whereas, the solubility conditions were inverse
for MET. The chromatographic conditions were optimized by dif-
ferent means (using different columns, different mobile phase
combination and different organic phases). Early chromatographic
work was performed with different brands of C8 and C18 columns
as stationary phase and various combinations of mobile phase with
pH in the range of 2.5–4.0, organic phases (ACN and/or Methanol),
stepwise. The flow rate of mobile phase was varied within 1.0–
1.5 mL min1. Wavelength for monitoring the eluent was selected
by scanning standard solution of drugs within 400 to 200 nm using
double beam UV–Visible spectrophotometer (Shimadzu 1800,
Japan).
Different HPLC methods were developed and optimized for
retention of MET & GLBN and AMLO & ATOR and combination of
all actives.
Optimum separation conditions were obtained with a Water’s
Nova pack Phenyl (150 mm  4.6 mm, i.d. 5.0 lm) column with
mobile phase consisting of 0.1% Phosphoric acid (pH 3.0) and ace-
tonitrile (ACN) in gradient mode with column oven temperature
maintained at 30 C and elution monitored by a UV detector at
227 nm.
All noted measurements were performed with an injection vol-
ume of 20 lL of samples dissolved in a diluent consist of aqueous
phase and organic phase in the ratio of 2:3, respectively. During
development of bioanalytical procedure, diluent was changed
accordingly.
2.3. Preparation of standard and resolution solution
Diluted standard solutions of each analyte representing
10 lg mL1 concentrations were prepared with diluent. Ranitidine
(IS-1) was used as internal standards for hydrophilic analyte i.e.
MET. Rosiglitazone (IS-2) was used as internal standards for lipo-
philic analytes such as AMLO, GLBN and ATOR. All-in-one resolu-
tion solution containing 10 lg mL1 each of MET, AMLO, GLBN
and ATOR and 5.0 lg mL1 each of IS-1 and IS-2 was prepared from
respective stock solutions.
For optimization purposes, a 20 lL of resolution solution was
injected into chromatograph and system suitability parameters
viz. % RSD of peak area for six injections of all analytes, % RSD of
retention time for six injections of all analytes, peak asymmetry
factor at 10% peak height and resolution were studied.
2.4. Sample preparation and extraction
The protein precipitation was the preferred choice of separation
because of the minimized steps in extraction of drug from matrix.
The method was attempted using 10% trichloroacetic acid (TCA)
and ACN and combination thereof. It was carried out by and 1 part
of plasma, 0.1 part drug and 0.05 parts of I.S. Diluted standard solu-
tion containing all analytes (15 lL) was added to 150 lL of plasma
previously spiked with internal standards in a 1.5 mL capacity
micro-centrifuge tube. The blend was subjected to vortex for about
5 min. The mixture was allowed to stabilize for two minutes then
100 lL of cold aqueous 10% (w/v) TCA was added and subjected to
alidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
Fig. 1. Chemical structure of (a) Amlodipine, (b) Atorvastatin, (c) Metformin, (d)
Glibenclamide, (e) Ranitidine and (f) Rosiglitazone.
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ronment, therefore, about 245 lL of ACN was added and mixture
was subjected to vortex for 5 min followed by centrifugation for
10 min at 15,000 rpm at 4 C. The blend was stabilized and allowed
to cool for 10 min, after that the blend was subjected to complete
dryness under Nitrogen. The sample was reconstituted with equal
volume of 0.1% phosphoric acid (pH 3.0) and Acetonitrile (ACN)
subjected to vortex for 2 min mobile phase. About 200 lL of super-
natant was collected and about 20 lL of sample was injected into
HPLC system.
2.5. Bioanalytical method validation
The developed HPLC conditions were validated as per USFDA
guideline for bioanalytical method validation.
2.5.1. Specificity
To demonstrate the specificity of the method blank plasma from
six different lots, spiked plasma samples and plasma samples
spiked with frequently prescribed medication were analysed.
Selectivity was established by injecting six samples at the lower
limit of quantitation (LLOQ) level and each of the six blank plasma
samples were tested for interference by comparing the mean peak
response obtained by injecting blank plasma samples to that of
mean peak response of LLOQ (10 ng mL1 for MET and ATOR,
25 ng mL1 for AMLO and 50 ng mL1 for GLBN). Representative
chromatograms were generated to show that other components
that could be present in the sample matrix are fully resolved from
the selected analytes. Dilution integrity and carry over effect were
also accessed to demonstrate specificity for the method.
2.5.2. Calibration curve
The standard curve was determined on each day of the six day
validation period; the slope, intercept and the correlation coeffi-
cient were determined. Each run consisted of a double control, sys-
tem suitability sample, blank samples (a plasma sample processed
without an IS), a zero sample (a plasma processed with IS), calibra-
tion curve consisting of 6–8 non-zero samples covering the total
range (LLOQ to 10,000 ng mL1 for MET, GLBN & ATOR and LLOQ
to 5000 ng mL1 for AMLO) and QC samples at three concentra-
tions (n = 6, at each concentration). Such runs were generated on
six consecutive days. Calibration samples were analysed from
low to high at the beginning of each run and other samples were
distributed randomly through the run. For calculation of the stan-
dard curve plots of peak area ratios against concentration were
used.
2.5.3. Sensitivity
The sensitivity (LLOQ) was determined by signal to noise ratio.
The resolution solution were serially diluted and spiked to the
human plasma and injections were made to obtain chromatogram.
Similarly, blank plasma samples were also processed and injected
into chromatograph. The LLOQ was expressed for the analyte con-
centration having response at least 5 times more compared to
blank response.
2.5.4. Precision and accuracy
Intraday precision, interday precision and the accuracy were
calculated from data obtained during a 6-day validation. Three
concentrations were chosen from the high medium and low range
of the standard curve as Quality Control (QC) samples. Plasma sam-
ples spiked at five concentrations i.e. LLOQ, low QC, medium QC,
high QC and ULOQ (were analysed at each day of the 6-day valida-
tion (n = 6 at each concentration). The concentration representingPlease cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
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and 10,000 ng/mL, respectively for MET. The concentration repre-
senting LLOQ, LQC, MQC, HQC and ULOQ level were 25, 100, 500,
1000 and 5000 ng/mL, respectively for AMLO. The concentration
representing LLOQ, LQC, MQC, HQC and ULOQ level were 50, 100,
500, 5000 and 10,000 ng/mL, respectively for GLBN. The concentra-
tion representing LLOQ, LQC, MQC, HQC and ULOQ level were 10,
100, 500, 1000 and 10,000 ng/mL, respectively for ATOR. Precision
was expressed as the coefficient of variation (%CV). Accuracy was
expressed as the mean relative error (%MRE). A precision and accu-
racy value (% CV) less than or equal to 15% for QC sample and less
than or equal to 20% for LLOQ were acceptable.
2.5.5. Recovery
Recovery of all analytes was evaluated by comparing the mean
peak response (peak area ratio of MET, AMLO, GLBN and ATOR with
respect to IS) of processed LLOQ, ULOQ and three QC samples to
mean peak response of unprocessed/without plasma of the same
concentration. Recoveries of actives and their respective IS were
evaluated by comparing the mean peak areas of processed samples
to mean peak areas of unprocessed reference solutions of the same
concentration.
2.5.6. Stability studies
The stability experiments were aimed at testing all possible
conditions that the samples might experience after collecting and
prior the analysis. The stability of the drug spiked at two QC levels
(LQC and HQC) for short term bench top (at room temperature for
4 h, 8 h, 16 and 24 h), freeze thaw (3 cycles; 20 C to room tem-
perature) and long term (30, 60 and 90 days at 20 C) were eval-
uated. Stability of all analytes in analytical solution was observed
at room temperature and in refrigerated conditions for period of
48 h.alidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
Fig. 2. Overlain chromatogram of representing elution of Metformin, Glibenclamide, amlodipine and atorvastatin in individual optimized HPLC conditions.
Fig. 3. Method development chromatograms representing (a) Simultaneous elution of metformin and Glibenclamide using gradient mode (b) simulation elution of
amlodipine and atorvastatin in isocratic mode and (c) Simultaneous elution of all analytes in initial gradient conditions.
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Table 1
Gradient pattern for co-elution of selected actives in optimized HPLC conditions.
Time (min) Aqueous phase Organic phase
0.01 60 40
3.00 60 40
6.00 45 55
8.00 20 80
10.00 10 90
12.00 60 40
P.K. Porwal, G.S. Talele / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxx 52.6. In vitro Protein binding studies
The protein binding studies were performed using ultrafiltra-
tion model [33]. The ultrafiltration technique is relatively simple,
robust and fast method for quantitation of analyte bound to
plasma protein [34]. The present assay has been used to quantify
the concentration of MET, AMLO, GLBN and in rHSA in drug–pro-
tein binding study. Plasma protein binding studies of all analytes
were performed using Amicon Ultra centrifugal filtration devices
(MWCO: 10 kDa). The all-in-one analyte solution was spiked to
rHSA to achieve drug concentration in the range of 1–10 lg/mL
of each analyte. To achieve equilibrium between the drug and
plasma proteins, the spiked protein samples were incubated at
37.4 C for at 20 rpm 90 min prior to ultrafiltration using Envi-
rogeine metabolic shaker. Samples of 0.5 mL volume were trans-
ferred and centrifuged at 2500g for 20 min at 4 C. Approximately,
200 lL of the ultrafiltrates were then collected. Glycosylated albu-
min was prepared and assayed by procedure given in literature
[35,36]. Similar protein binding experiments were performed using
glycosylated-albumin as exercised with HSA.3. Results and discussions
To achieve the objectives of work simple, sensitive, efficient,
robust, fast and economic HPLC method was developed and vali-
dated as per Bio-analytical method validation guidelines. The
developed and validated HPLC was employed to quantify drug con-
centration in ultrafiltrate.3.1. HPLC-UV method development
To get optimum separation conditions, various method devel-
opment strategies were systematically optimized. The methodFig. 4. System suitability chromatogram showing simultaneous elution of Metform
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ATOR from each other and peaks of human plasma. The selected
FDCs were containing combinations of hydrophilic (i.e. MET) and
lipophilic (i.e. AMLO, GLBN and ATOR) actives. Normal phase chro-
matography can be used for the separation of non-ionic and/or
non-polar substances, while reversed-phase chromatography (C8
and C18) can be used for the separation of non-ionic as well as
ion forming non-polar to medium polar substances.
Chemically MET is hydrophilic in nature. MET remains ionized
at working pH range for chromatography [37]. MET is a weak base
with a high pKa value (BH+, 13.41) shows very short retention on
reversed phase column [38]. Though some published reports indi-
cated retention of MET on reversed phase columns but the reten-
tion may be credited to free silanols present on the column
surface. In most of the reversed phase column MET was eluted
before column volume which does not favor its estimation in
plasma sample [39]. The retention behaviour of MET in normal
phase is opposite to that in reversed phase conditions. It should
show strong retention in normal phase chromatography. A bifur-
cated peak of MET was observed when it was extracted from
human plasma using cation exchange solid-phase extraction with
cation exchange-based HPLC separation with a normal-phase gra-
dient system using semi-micro LC/MS/MS [40]. At relatively basic
pH 7 of mobile phase, all the candidate drugs were eluted with
peak asymmetry factor more than 2.2 owing to full protonation
of MET, AMLO, GLBN and ATOR at alkaline pH. The ionization con-
stant (pKa in conjugated acid form; i.e. HA) values for AMLO, GLBN
and ATOR were less than 5, therefore the pH of mobile phase kept
about 2.5 to 3.5 to get unionised form of AMLO, GLBN and ATOR.
The chemical properties of MET were unfavorable for its retention
on a mere reversed-phase HPLC conditions (Fig. 1).
Though the physiochemical properties of MET was not favor-
able for its retention in RP-HPLC on the other hand the retention
of other analytes viz. AMLO, GLBN and ATOR was favorable for their
retention on an reversed phase column. Various trials were made
to optimize co-elution of all selected analytes in a single HPLC
run. In the first trial the retention of MET, AMLO, ATOR and GLBN
was observed in reversed phase conditions. The stationary phase
and other system conditions were kept same except the analytical
wavelength of interest. An overlain chromatogram representing
elution of individual analyte in RP-HPLC conditions is shown in
Fig. 2. The capacity factor for AMLO, ATOR and GLBN was in the
range of 2.5–5.0 except for MET, where the value of capacity factor
was less than 0.5. Aside that bifurcation was observed in the peakin, amlodipine, Glibenclamide and atorvastatin in optimized HPLC conditions.
alidated HPLC-UV method for simultaneous determination of Metformin,
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Table 2
Results of system suitability parameters for MET, AMLO, GLBN and ATOR (n = 6) in optimized HPLC conditions.
System suitability parameters MET AMLO GLBN ATOR
Retention time (min) 3.6 8.9 9.9 11.0
% RSD of peak area 1.66 1.41 1.84 1.21
Capacity factor (k’) 1.32 4.74 5.39 6.10
Peak asymmetry factor (at 10% height) 1.41 1.33 1.37 1.12
Resolution 9.8 6.3 9.5 10.8
Fig. 5. Overlain chromatogram showing elution of all analytes to spiked human plasma with blank processed plasma.
Table 3
List of drugs not interfering with retention time of analyte of interest.
Name of drugs commonly prescribed in diabetes
Aspirin Atenolol Pioglitazone
Nateglinide Codeine Paracetamol
Glimepiride Lisinopril Ambroxol
Terbutaline Furosemide Hydrochlorothiazide
Itraconazole Candersartan Levofloxacin
Fluconazole Valsartan Nifedipine
Fenofibrate Irbesartan Nevivolol
Metaprolol Simvastatin Carvedilol
Diclofenac Telmisartan Furosemide
Rabeprazole Sitagliptine Domperidone
Ciprofloxacin Amphotericin B Enalapril
Captopril
6 P.K. Porwal, G.S. Talele / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxof MET may be due to incomplete ionization of MET at pH 3.0. The
RP-HPLC trials were taken at equal Ratio of aqueous (0.1% Phos-
phoric acid; pH 3.0) to organic phase with C18 stationary phase
(HiQ Sil 250  4.6 mm i.d.; 5 lm particle size). The capacity factor
of MET was not enhanced with any modification in the RP-HPLC
conditions.
In the next approach, the nature of stationary phase was
changed from highly non-polar (i.e. -C18) to moderately
non-polar (i.e. -Phenyl) and HPLC methods was developed for
simultaneous/co-elution of two drug at a time. Initially, HPLC
method was developed for simultaneous estimation of MET and
GLBN using gradient programming. Additionally, ranitidine was
used as internal standard to the HPLC method. A platue? linear
ramp of 7.5%/min increment of organic phase? platue gradient
program was employed for elution of MET and GLBN as shown in
Fig. 3a. The capacity factor for MET and GLBN was about 1.5 and
6.0, respectively. The system suitability parameters were success-
fully achieved and method was optimized for co-elution of thesePlease cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
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simultaneous/co-elution of AMLO and ATOR under the similar
chromatographic conditions. An isocratic combination of aqueous
to organic phase in the Ratio of 40:60 was used and HPLC method
was developed and validated for simultaneous elution of these two
drugs. The research work was developed by our research group
separately and published earlier [ref IJPS], the representative chro-
matogram is given in Fig. 3b.
Further, the developed and optimized HPLC methods for these
two combinations (MET & GLBN, AMLO & ATOR) were joined
together using a gradient program (Fig. 3c). Though all drugs were
eluted in non-interfered manner and the results of system suitabil-
ity parameters were passed, but the total run time was more than
20.0 min. The gradient program was further modified to reduce the
total run time of the HPLC method as shown in Table 1.
In the attempt for selection of Internal Standard, Ranitidine and
rosiglitazone were eluted in the optimized chromatographic condi-
tions of MET, AMLO, ATOR and GLBN. The IS-1 (Ranitidine) was
used to simulate the chromatographic elution of MET, Whereas,
IS-2 (Rosiglitazone) was used for hydrophobic analytes. The active
and selected IS were scanned from 400 to 200 nm. All the drugs
and their respective IS have shown optimum response at 228 nm,
therefore this wavelength was selected as wavelength for working.
(UV-spectrum is provided as supplement to this article)
The representative chromatogram of MET, AMLO, ATOR and
GLBN with their respective IS in optimized conditions is given in
Fig. 4. The results of system suitability studies were given in
Table 2.3.2. Extraction procedure
Efficient extraction of mixture of polar to non-polar analyte was
performed using protein precipitation technique. Aside that,alidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
Fig. 6. Overlain chromatogram showing elution of all analytes to spiked human plasma at LLOQ level with blank processed plasma.
Table 4
Comparison of Weighted and Unweighted calibration curves.
Name of drug Calibration range (ng/mL) Unweighted linearity curve 1/X2 weighted linearity curve 1/X2 weighted linearity curve
m c %MRELLOQ m c %MRELLOQ m c %MRELLOQ
MET 10–10,000 3.2 2.9  102 155.65 2.04 3.1  102 23.14 2.23 4.2  102 10.25
AMLO 25–5000 2.11 4.0  102 32.65 1.60 2.8  103 37.85 1.84 8.3  103 9.11
GLBN 50–10,000 2.88 2.8  102 121.21 1.88 2.4  102 12.54 1.54 2.8  102 9.88
ATOR 10–5000 1.61 6.6  103 102.56 1.55 1.8  102 51.02 1.69 2.9  103 12.36
m and c are slope and y-intercept, respectively, for line equation of y = mx + c. and %MRELLOQ is %Mean relative error at LLOQ level.
Table 5
Results of Precision & Accuracy batch data for MET, AMLO, GLBN and ATOR in plasma (n = 6).
Nominal Concentration in ng/mL Precision (% CV) Accuracy (Mean% relative error)
Intra-day Inter-day Intra-day Inter-day
MET
10 (LLOQ) 11.42 14.50 4.98 5.68
100 (LQC) 5.62 7.98 3.11 1.90
500 (MQC) 6.22 9.42 6.13 8.15
5000 (HQC) 11.99 12.63 8.66 10.23
10,000 (ULOQ) 7.65 13.24 4.43 5.21
AMLO
25 (LLOQ) 15.61 18.57 9.50 9.28
100 (LQC) 13.21 14.88 5.55 7.83
500 (MQC) 10.28 12.19 4.18 8.24
1000 (HQC) 13.01 14.36 3.24 5.63
5000 (ULOQ) 12.99 13.65 2.52 3.92
GLBN
50 (LLOQ) 14.22 16.52 5.12 6.38
100 (LQC) 10.23 9.88 5.81 7.18
500 (MQC) 9.87 10.11 5.27 7.11
5000 (HQC) 3.14 4.83 2.97 3.84
10,000 (ULOQ) 2.99 3.65 1.52 1.77
ATOR
10 (LLOQ) 14.75 15.09 5.58 7.22
100 (LQC) 13.04 13.33 5.81 10.82
500 (MQC) 10.25 12.34 4.82 4.73
1000 (HQC) 8.34 9.78 1.94 4.34
10,000 (ULOQ) 2.98 5.95 2.49 5.65
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[41]. Various protein precipitating agents like acetonitrile, metha-
nol and cold aqueous trichloroacetic acid (TCA) solution and com-
bination thereof were used for extortion of the analytes formPlease cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
Amlodipine, Glibenclamide and Atorvastatin in human plasma and applicatio
http://dx.doi.org/10.1016/j.bfopcu.2016.10.002plasma. The highest recovery (>95.0%) of MET was observed with
cold aqueous 10% solution of TCA. The recoveries of AMLO, GLBN
and ATOR ranged from 47.7% to 61.9% in TCA solution whereas,
the recoveries were ranging from 79.85% to 91.26% in ACN at testalidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
Table 6
% Mean recoveries for MET, AMLO, GLBN and ATOR in finally optimized HPLC method.
Concentration % Mean recovery for MET (n = 6) % Mean recovery for AMLO (n = 6) % Mean recovery for GLBN (n = 6) % Mean recovery for ATOR (n = 6)
LLOQ 93.54 ± 6.44 87.54 ± 10.21 86.98 ± 8.13 90.92 ± 12.34
LQC 92.82 ± 3.63 89.97 ± 8.87 90.12 ± 4.25 89.46 ± 9.97
MQC 93.71 ± 2.99 90.99 ± 2.57 90.99 ± 5.89 90.88 ± 8.12
HQC 94.83 ± 3.07 88.53 ± 4.13 92.54 ± 3.89 90.26 ± 4.43
ULOQ 91.97 ± 3.87 91.02 ± 5.36 94.59 ± 2.36 94.07 ± 5.21
Mean ± SD* 93.37 ± 1.07 (1.14) 89.61 ± 1.54 (1.72) 91.044 ± 2.84 (3.12) 91.19 ± 1.75 (0.92)
* Numbers in brackets were RSD.
Table 7
Stability of MET, AMLO, GLBN and ATOR at LQC and HQC level.
Stability % Mean change
MET AMLO GLBN ATOR
Bench top Room temperature (24 h) LQC 4.11 5.24 6.12 6.15
HQC 3.15 2.86 0.98 3.19
Freeze and thaw After 3rd cycle at 20 C LQC 2.34 6.23 8.81 7.49
HQC 1.24 2.51 6.54 5.13
Long term stability 90 days at 20 C LQC 6.07 5.91 8.52 2.42
HQC 1.85 0.95 4.65 2.01
Fig. 7. Overlain chromatogram of ultrafiltrate sample quantifying all analytes in rHSA and Gly-HSA.
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solubility of selected analytes in organic solvents. Therefore, mix-
ture of TCA and ACN was used as precipitating media.
Plasma previously spiked with internal standard (0.05 part) was
spiked with 0.1 part of all-in-one drug solution. The plasma-drug
blend was precipitated with 0.5 part of TCA. At the end of precip-
itation, supernatant was subjected to complete dryness under
nitrogen and mixed with mobile phase to make the sample more
compatible with the optimized method. The % mean recovery for
MET, AMLO, GLBN and ATOR was 92.6, 90.2, 86.4 and 88.8%,
respectively. A representative chromatogram of all analytes in
the developed extraction condition is given in Fig. 5.
3.3. Bioanalytical method validation
The developed method was validated for its specificity, sensitiv-
ity, calibration curve, recovery, precision, accuracy and stability as
per bioanalytical method validation guideline suggested by USFDA.Please cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
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The specificity of optimized bioanalytical HPLC method was
evaluated by observing interference due to various biological fluids
and commonly prescribed medications in diabetes and pharma-
cotherapy for its secondary complications. A list of co-medicated
drugs, those were evaluated for interference, is given in Table 3.
While accessing specificity, interferences due to matrix and
injection carryover were observed at retention time of all actives
and their respective IS. No- interference was observed at retention
time of any analyte. A representative chromatogram of all analytes
at LLOQ level overlain with blank is shown in Fig. 6. There blank
analysis gave no responses at the retention times of the peaks of
interest clarify absence of endogenous substances in the plasma
that may interfere with the other peaks of interest. Concentrations
down to the LLOQ were detected with acceptable accuracy and
precision using this method (CV% and RE% < 15%). The mean back-
ground response of blank was also calculated and found to be less
than 20% of the response at the Limit of Quantification. The LLOQalidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
Fig. 8. Graph representing difference in bound pattern of Amlodipine, Glibenclamide and Atorvastatin in rHSA (_________) and Gly-HSA ( - - - - - -).
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retention of MET. The mean background was also calculated and
found to be 15.9% (MET), 11.4% (AMLO), GLBN (13.9%), 10.6%
(ATOR), 4.85% (IS-1) and 4.78% (IS-2) in selected conditions. Aside
that, mean background interferences at the retention of all internal
standards (% background interference less than 5%) were also in
limits (Table 4).
3.3.2. Standard curve and linearity
The calibration curve was determined on each day of the 6-day
validation, the slope, the intercept and the correlation coefficient
was determined. By examining the calibration curves it was
concluded that the relationship between peak area ratio and
concentration was linear for weighted calibration curve. The %
Mean relative error in recovery calculation at LLOQ level was
least (<15%) for 1/2 weighted calibration curve when a weight
of 1/ and 1/2 was applied. The results of unweighted and
weighted calibration curves and mean% relative error at LLOQ
was given in Table 7.Please cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
Amlodipine, Glibenclamide and Atorvastatin in human plasma and applicatio
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The values obtained, during the six-day validation period, for
plasma intraday and inter-day precision and accuracy were sum-
marized in Table 5. All values of accuracy and precision were
within recommended limits. Intraday precision ranged from
2.99% to 15.61% whereas the inter-day precision was from 3.65%
to 18.57%. The intraday mean error was from 9.50% to 5.81%
whereas the inter-day mean% relative error was from 10.23% to
5.65%.
3.3.4. Recovery studies
The extraction recovery was calculated at LLOQ, QC samples,
ULOQ level (n = 6). The highest recovery at 10 lg/mL concentration
was obtained for MET (>90.0%) using protein precipitation method
when 10% cold Aq. Solution of TCA alone was used whereas, GLBN
(<50.35%) have lowest recovery for the same. The recoveries of
AMLO and ATOR were ranged from 47.7% to 61.9% in TCA solution,
whereas; the recoveries were ranging from 79.85% to 91.26% in
ACN at test concentration level (i.e. 10 lg/mL). A combination of
alidated HPLC-UV method for simultaneous determination of Metformin,
n to protein binding studies, Bulletin Facult Pharmacy Cairo Univ (2016),
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mean % recovery in finally optimized protein precipitation method
are given in Table 6.3.3.5. Stability
Stock solution of MET, AMLO, GLBN and ATOR and their IS were
stable at room temperature for 24 h and at 2–8 C for 48 h. MET,
AMLO, GLBN and ATOR analytes in control Human plasma at room
temperature were stable at least for 24 h and for minimum of three
freeze and thaw cycles. Spiked plasma samples, stored at 20 for
long term stability experiment, were stable for minimum of
90 days. Different stability experiments in plasma with values for
precision and per cent change are shown in Table 7.3.4. Plasma protein binding
The validated bioanalytical HPLC method has been successfully
applied to quantify the concentration of MET, AMLO, GLBN and
ATOR in ultrafiltrate using ultrafiltration as drug–protein binding
study model [41]. MET has been reported to induce conformational
changes in HSA [23]. In an earlier published work from our labora-
tory we had reported that MET bind with rHSA and Gly-HSA in a
concentration-independent manner. The binding of MET was not
altered in the presence of co-spiked actives. Whereas, high protein
bound drugs viz. AMLO, GLBN and ATOR has shown 4–5 fold incre-
ment in their unbound fraction relative to their respective binding
fraction when observed alone. Further the unbound fraction of
highly albumin bound drugs was increased nearly to double when
incubated with Gly-HSA as compare to HSA. An overlain chro-
matogram of actives in ultrafiltrate from HSA and Gly-HSA was
shown in Fig. 7.
The graph showing concentration dependent pattern for bound
fraction of high protein bind actives (i.e. AMLO, GLBN and ATOR) is
shown in Fig. 8. As shown in the graph, the binding of AMLO and
GLBN was increased in concentration dependent manner both to
HSA and Gly-HAS. Whereas, the binding pattern of ATOR to serum
albumin was ambiguous.4. Conclusion
We have validated a HPLC-UV method for quantitation of polar
(MET) and non-polar (AMLO, GLBN and ATOR) analytes, simultane-
ously, in small sample quantity with sufficient accuracy and preci-
sion. The method has utilized simple mobile phase with less non-
polar stationary phase. The extraction procedure was also simple,
economic and efficient. The total run time was less than 12.0 min
and could be proved as better alternative for costly liquid
chromatographic-mass spectrometric method.
Metformin plus sulfonylurea is first line treatment for non-
insulin dependent diabetes mellitus. Amlodipine plus Atorvastatin
combination is frequently prescribed to diabetic patient with
hypertension and dyslipidemia. Metformin induce conformational
changes in human serum albumin structure but does not bind to
albumin, at the same sulfonylurea drugs are high albumin bind
actives. We had observed a three to five fold increase in unbound
fraction of Glibenclamide, when it was incubated with amlodipine
and atorvastatin. The unbound fraction of highly protein bound
drugs viz. Amlodipine, Glibenclamide and Atorvastatin was
increased nearly to double when incubated with glycated-
albumin as compare to rHSA. A sum total of 10–15% increase in
unbound fraction of high protein bound drugs was observed when
prescribed alone. Thus apposite estimation of protein binding
capacity of high protein bound drugs in chronic diabetes provides
better control over fluctuation of serum glucose level.Please cite this article in press as: P.K. Porwal, G.S. Talele, Development of v
Amlodipine, Glibenclamide and Atorvastatin in human plasma and applicatio
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